The global landscape of tuberculosis therapeutics

Jeffrey A. Tornheim; Kelly E. Dooley

doi:10.1146/annurev-med-040717-051150

The global landscape of tuberculosis therapeutics

Jeffrey A. Tornheim, Kelly E. Dooley

School of Medicine

Research output: Contribution to journal › Review article › peer-review

10 Scopus citations

Abstract

Tuberculosis (TB) is one of the oldest infections afflicting humans yet remains the number one infectious disease killer worldwide. Despite decades of experience treating this disease, TB regimens require months of multidrug therapy, even for latent infections. There have been important recent advances in treatment options across the spectrum of TB, from latent infection to extensively drug-resistant (XDR) TB disease. In addition, new, potent drugs are emerging out of the development pipeline and are being tested in novel regimens in multiple currently enrolling trials. Shorter, safer regimens for many forms of TB are now available or are in our near-term vision. We review recent advances in TB therapeutics and provide an overview of the upcoming clinical trials landscape that will help define the future of worldwide TB treatment.

Original language	English (US)
Pages (from-to)	105-120
Number of pages	16
Journal	Annual review of medicine
Volume	70
DOIs	https://doi.org/10.1146/annurev-med-040717-051150
State	Published - Jan 27 2019

Keywords

dose optimization
drug resistance
latent tuberculosis infection
tuberculosis

ASJC Scopus subject areas

General Biochemistry, Genetics and Molecular Biology

Access to Document

10.1146/annurev-med-040717-051150

Cite this

@article{9d8233c1dd7c44328364b1cd3aebdef2,

title = "The global landscape of tuberculosis therapeutics",

abstract = "Tuberculosis (TB) is one of the oldest infections afflicting humans yet remains the number one infectious disease killer worldwide. Despite decades of experience treating this disease, TB regimens require months of multidrug therapy, even for latent infections. There have been important recent advances in treatment options across the spectrum of TB, from latent infection to extensively drug-resistant (XDR) TB disease. In addition, new, potent drugs are emerging out of the development pipeline and are being tested in novel regimens in multiple currently enrolling trials. Shorter, safer regimens for many forms of TB are now available or are in our near-term vision. We review recent advances in TB therapeutics and provide an overview of the upcoming clinical trials landscape that will help define the future of worldwide TB treatment.",

keywords = "dose optimization, drug resistance, latent tuberculosis infection, tuberculosis",

author = "Tornheim, {Jeffrey A.} and Dooley, {Kelly E.}",

note = "Publisher Copyright: {\textcopyright} 2019 by Annual Reviews.",

year = "2019",

month = jan,

day = "27",

doi = "10.1146/annurev-med-040717-051150",

language = "English (US)",

volume = "70",

pages = "105--120",

journal = "Annual review of medicine",

issn = "0066-4219",

publisher = "Annual Reviews Inc.",

}

TY - JOUR

T1 - The global landscape of tuberculosis therapeutics

AU - Tornheim, Jeffrey A.

AU - Dooley, Kelly E.

PY - 2019/1/27

Y1 - 2019/1/27

N2 - Tuberculosis (TB) is one of the oldest infections afflicting humans yet remains the number one infectious disease killer worldwide. Despite decades of experience treating this disease, TB regimens require months of multidrug therapy, even for latent infections. There have been important recent advances in treatment options across the spectrum of TB, from latent infection to extensively drug-resistant (XDR) TB disease. In addition, new, potent drugs are emerging out of the development pipeline and are being tested in novel regimens in multiple currently enrolling trials. Shorter, safer regimens for many forms of TB are now available or are in our near-term vision. We review recent advances in TB therapeutics and provide an overview of the upcoming clinical trials landscape that will help define the future of worldwide TB treatment.

AB - Tuberculosis (TB) is one of the oldest infections afflicting humans yet remains the number one infectious disease killer worldwide. Despite decades of experience treating this disease, TB regimens require months of multidrug therapy, even for latent infections. There have been important recent advances in treatment options across the spectrum of TB, from latent infection to extensively drug-resistant (XDR) TB disease. In addition, new, potent drugs are emerging out of the development pipeline and are being tested in novel regimens in multiple currently enrolling trials. Shorter, safer regimens for many forms of TB are now available or are in our near-term vision. We review recent advances in TB therapeutics and provide an overview of the upcoming clinical trials landscape that will help define the future of worldwide TB treatment.

KW - dose optimization

KW - drug resistance

KW - latent tuberculosis infection

KW - tuberculosis

UR - http://www.scopus.com/inward/record.url?scp=85060577065&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85060577065&partnerID=8YFLogxK

U2 - 10.1146/annurev-med-040717-051150

DO - 10.1146/annurev-med-040717-051150

M3 - Review article

C2 - 30403551

AN - SCOPUS:85060577065

SN - 0066-4219

VL - 70

SP - 105

EP - 120

JO - Annual review of medicine

JF - Annual review of medicine

ER -

The global landscape of tuberculosis therapeutics

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this